26 May 2020
Characterized by a buildup of amyloid plaques in the brain, Alzheimer’s is an irreversible disease that leads to memory loss and a decrease in cognitive function. More than 5 million Americans suffer with the brain condition, which is the sixth leading cause of death in the United States. While the causes of Alzheimer’s are not fully understood, scientists believe genetic, lifestyle and environmental factors are involved in the disease’s development.
20 May 2020
Scientists have collected plenty of evidence linking exercise to brain health, with some research suggesting fitness may even improve memory. But what happens during exercise to trigger these benefits? New UT Southwestern research that mapped brain changes after one year of aerobic workouts has uncovered a potentially critical process: Exercise boosts blood flow into two key regions of the brain associated with memory. Notably, the study showed this blood flow can help even older people with memory issues improve cognition, a finding that scientists say could guide future Alzheimer’s disease research.
6 May 2020
Cortexyme Publishes Data on P. gingivalis' Ability to Infect Neurons, drive Alzheimer’s-Like Pathology
Cortexyme, Inc., a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s disease and other degenerative diseases, today announced the publication of research further documenting the ability of the pathogen Porphyromonas gingivalis to invade neurons and trigger Alzheimer’s-like neuropathology.
7 April 2020
Exercise in older adults, even at an advanced stage of dementia, is an important strategy to maintain independence in everyday living and to promote quality of life. The research group "geriatric psychiatry in motion" of the German Sport University Cologne and the LVR-Hospital Cologne develop and evaluate exercise programs for geriatric mental health care. Latest results from a study in acute dementia care indicate a special exercise program is not only effective for the patients themselves, but also reduces the professional caregiver’s burden caused by neuropsychiatric symptoms.
14 February 2020
A study published in JAD from researchers at McGill University led by Dr. Claudio Cuello of the Department of Pharmacology and Therapeutics, has shown that, when given in a formulation that facilitates passage to the brain, lithium in doses up to 400 times lower than what is currently being prescribed for mood disorders is capable of both halting signs of advanced Alzheimer's pathology such as amyloid plaques and of recovering lost cognitive abilities.
23 January 2020
Mild Cognitive Impairment: ISS Produces the First Epidemiological Estimation of the Phenomenon Among Migrants in Europe
In a study published in the Journal of Alzheimer's Disease, ISS researchers estimated about 680,000 cases of mild cognitive impairment (MCI) in a total of 12,730,960 migrants, aged between 60 and 89 years, living in the European Union (EU) in 2018.
20 January 2020
A new study published in the Journal of Alzheimer's Disease (JAD) supports a growing body of research that links human exposure to aluminum with Alzheimer's disease (AD). Researchers found significant amounts of aluminum content in brain tissue from donors with familial AD. The study also found a high degree of co-location with the amyloid-beta protein, which leads to early onset of the disease.
22 December 2019
To the medical community’s surprise, several studies from the US, Canada, and Europe suggest a promising downward trend in the incidence and prevalence of dementia. Important risk factors for dementia, such as mid-life obesity and mid-life diabetes, have been increasing rapidly, so the decline in dementia incidence is particularly perplexing.
27 November 2019
New Study Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-Moderate Alzheimer's Disease
TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer’s disease. These results showed that the drug produced concentration-dependent effects on cognitive decline and brain atrophy.
26 November 2019
Miharu Nakanishi, Chief Researcher of Tokyo Metropolitan Institute of Medical Science, and her colleagues finds that psychological well-being at 52 years were prospectively associated with cognitive function at 69 years. The authors used data in women from the British 1946 birth cohort in the Medical Research Council’s National Survey of Health and Development. There was a significant association between greater personal growth and lower self-acceptance at 52 years, and better cognition at 69 years.